MLANA and cancer: A clinical trial of Melan-A (MART-1)-targeted adoptive T-cell transfer therapy for metastatic melanoma revealed that TNF-α secreted by infiltrated CTLs induced dedifferentiation of melanoma cells to lose MART-1 and gp100 expression and acquire NGFR expression, leading to resistance to cancer immunotherapy (68).